Clinical trial

Acute Effect of Exenatide on Brain Glucose Metabolism

NCT01588418

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-07-01

PhasePHASE4

Study timeline

Study start (unknown)2010-07-01Date precision: month

Registry last updated2017-11-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Impaired Glucose Tolerance (IGT)unresolved

Diabetesunresolved

Interventions

ExenatideDRUG · verified · RxNorm: exenatide

PlaceboDRUG

Sponsors & collaborators

The University of Texas Health Science Center at San Antoniolead sponsor

Amylin Pharmaceuticals, LLC.collaborator

Mapped research locations

San AntonioTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01588418 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.